文献速递泌尿生殖腹部MR

专用前列腺多参数磁共振活检前检查项目三年经验及其对限时癌症诊断路径的影响

Three-year experience of a dedicated prostate mpMRI pre-biopsy programme and effect on timed cancer diagnostic pathways.
PubMed 文献 · Clin Radiol · 2019-07-06

本研究评估活检前磁共振成像对前列腺癌诊断时间的影响,并报告磁共振引导下的病理结果。30个月内1483例疑似前列腺癌患者中,745例接受前置MRI,其中332例在专用扫描时段前15个月(组1),413例在引入后15个月(组2)。结果显示预留MRI时段缩短了诊断时间,前置MRI在保持预期临床显著癌检出率的同时安全避免了大量活检。

要点

  • 前置MRI联合预留扫描时段使28天内完成诊断的比例从66.9%提升至81.1%,中位诊断时间从25.5天降至20.9天。
  • 阴性MRI(Likert 1-2)对Gleason≥3+4的阴性预测值为92.8%,对≥4+3为98.3%。
  • 经会阴活检达到28天标准的比例(29.7%)显著低于经直肠活检(67.4%,p<0.0001)。

核心结论

  • 预留MRI扫描时段可缩短诊断时间;前置MRI在保持预期临床显著癌检出率的同时,安全地使相当比例男性避免活检。

研究设计与样本

  • 单中心(原文未明确说明中心数)30个月期间1483例疑似前列腺癌患者的前置MRI项目评估;745例接受前置MRI(组1 332例,组2 413例),另88例在临床评估后行初始MRI;活检采用经直肠或经会阴途径,MRI靶向灶使用MRI/超声融合;临床显著癌定义为Gleason≥3+4,阴性MRI定义为Likert 1-2。

诊断标准与关键数值

  • 阴性MRI定义为Likert 1-2;临床显著癌定义为Gleason≥3+4;阴性MRI对Gleason≥3+4的阴性预测值为92.8%,对Gleason≥4+3的阴性预测值为98.3%;484/833(58.1%)MRI为阴性,其中37.4%接受了活检;323例MRI阳性病例中任何癌存在率78.9%(临床显著癌60.4%);总体前列腺癌患病率34.3%(临床显著癌24.6%)。

临床应用与阅片要点

  • 前置MRI可用于避免不必要活检,阴性MRI(Likert 1-2)对临床显著癌有较高阴性预测值;经会阴活检达到28天诊断标准的比例显著低于经直肠活检,可能影响诊断路径时限。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

AIM: To evaluate the effect of pre-biopsy magnetic resonance imaging (MRI) on cancer diagnostic times, and to report MRI-directed pathology outcomes.

MATERIALS AND METHODS: In total, 1483 patients were referred with prostate cancer suspicion during a 30-month period. Upfront MRI was performed in 745 patients: 332 MRIs in the 15 months prior to dedicated scanning slots (group 1), and 413 in the 15 months post-introduction (group 2). A further 88 patients had initial MRI following clinical assessment. Biopsy via the transrectal (TR) or transperineal (TP) approach was performed, with MRI/ultrasound fusion for MRI targets. Clinically significant cancer (csPCa) was defined as Gleason ≥3+4. Negative MRIs were defined as Likert 1-2. Per-case clinical decisions were taken to biopsy or not.

RESULTS: 44.4% of patients avoided biopsy. 484/833 (58.1%) MRIs were negative; 37.4% of these patients had biopsy with a negative predictive value (NPV) of 92.8% for Gleason ≥3+4 and 98.3% for ≥4+3. Overall prostate cancer prevalence was 34.3% (24.6% csPCa). In 323 MRI-positive cases, any cancer was present in 78.9% (csPCa 60.4%). Of the 1483 patients, 1232 (83.1%) completed all diagnostic tests within 28 days. Upfront MRI patients met this standard in 621/833 (74.5%), improving from 66.9% to 81.1% with reserved slots (group 2) with a reduced diagnostic time from median 25.5 to 20.9 days. Biopsy scheduling delayed the pathway in 69.7%, with MRI responsible in 22.3%, reducing to 10.3% in group 2. TP biopsies met the 28-day standard in significantly less cases (29.7%), compared to TR (67.4%, p<0.0001).

CONCLUSION: Reserved MRI slots reduces time-to-diagnosis, and upfront MRI safely avoids biopsy in a significant proportion of men, whilst maintaining expected csPCa detection rates.

来源:Clin Radiol,查看原文。版权归原作者所有。

引用

  1. Barrett T, Slough R, Sushentsev N, et al. Three-year experience of a dedicated prostate mpMRI pre-biopsy programme and effect on timed cancer diagnostic pathways. Clin Radiol. 2019. PMID: 31288924. doi:10.1016/j.crad.2019.06.004

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。